TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05888844
Drug: INCB099280
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm description.
Study: NCT05382442
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine via oral,The total daily dose was 2000mg/sqm, Each cycle was administered for 2 consecutive weeks, followed by a week of rest, with a treatment cycle every 21 days
Study: NCT05382442
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Leucovorin via IV infusion
Study: NCT05430035
Drug: HIPEC
Normalized name: Hyperthermic Intraperitoneal Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heated Intra-Peritoneal Chemotherapy (HIPEC) HIPEC will be performed at the time of the index operation if a cancer is known pre-operatively, at the time of re-operation for incidentally discovered cancers already treated with cholecystectomy that are undergoing central hepatectomy and portal lymphadenectomy as part of standard of care, or independently if no other procedures are indicated. A closed technique will be utilized to deliver mitomycin C (MMC) over the first 60 minutes followed by an additional smaller dose over an additional 30 minutes. Perfusate will be heated to obtain a tissue temperature of 42°
Study: NCT04980222
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive 50 mg/m2 body surface area of doxorubicin IV as per schedule specified in the treatment arm.
Study: NCT05088460
Drug: REGN4461
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) infusion loading dose followed by subcutaneous (SC) injection weekly (QW).
Study: NCT05088460
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) infusion loading dose followed by subcutaneous (SC) injection weekly (QW).
Study: NCT04980222
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive 750 mg/m2 body surface area of cyclophosphamide IV as per schedule specified in the treatment arm.
Study: NCT06389942
Drug: 9MW3011
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose intravenously on day 1
Study: NCT06454266
Drug: ORM regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects received ORM regimen treatment every 21 days for a total of 6 cycles. The specific medication is as follows  Obutinib tablets 150mg qd d1-21 (suspended 2 days before MTX use until MTX drops to safe concentration) Rituximab 375mg/m2, d1 Methotrexate 3g/m2, d2
Study: NCT06558071
Drug: Galatonol 300 mg/Striatin 30 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 film-coated caplet of Herba Asimor, twice daily
Study: NCT06558071
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 film-coated caplet of placebo Herba Asimor, twice daily
Study: NCT05064878
Drug: Matching ZX008 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching ZX008 placebo is supplied as an oral solution.
Study: NCT05929937
Drug: Opioids
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive a prescription of 5 tablets of opioids (preferred: Oxycodone, or surgeon preference for Oxycodone intolerance)
Study: NCT05496595
Drug: DCBY02
Approvals — FDA: no, EMA: no, PMDA: no
Description: A monoclonal antibody that binds to CD93, DCBY02 will be administered as a single intravenous (IV) infusion on Day 1 in each 21-day cycle.
Study: NCT05358249
Drug: JDQ443
Approvals — FDA: no, EMA: no, PMDA: no
Description: KRAS G12C inhibitor, oral
Study: NCT03825965
Drug: Placebo oil for oral use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is Medium-chain triglycerides oil with identical features (in appearance, flavour, and odour) to the MPL-001 oil.
Study: NCT06492031
Drug: Glucose Peritoneal Dialysis Solution
Normalized name: glucose Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment modality, number of daily dialysate exchanges, dialysate concentration, exchange dosage of dialysate, duration of dwell, and length of treatment for PD patients as determined by the clinician.
Study: NCT05523687
Drug: [14C]-PC14586
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single, oral dose of \[14C\]-PC14586
Study: NCT05446480
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ingestion 10mg inert pill 2 hours prior to heat strain trial. Second dose 24-hours later.
Study: NCT05072093
Drug: Offering of on-demand oral PrEP
Normalized name: Vitafol-One Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: For men who are not interested in daily oral PrEP or plan to discontinue daily oral PrEP, the investigators will offer on-demand oral PrEP (Truvada) which will allow them to take it immediately before/after a sexual encounter. It is hoped that this will serve as an alternative to daily oral PrEP use that is desirable for some people.
Study: NCT06486662
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a Single Ascending Dose (SAD): 1 day single dose treatment and Multiple Ascending Doses (MAD): 16 days multiple dose treatment of Placebo
Study: NCT06347874
Drug: Cryoablation
Approvals — FDA: no, EMA: no, PMDA: no
Description: an injection of 1ml of 1% lidocaine per rib and ultrasound guided cryoablation of the intercostal nerves
Study: NCT06347874
Drug: ESP Catheter
Normalized name: CATHETER
Approvals — FDA: no, EMA: no, PMDA: no
Description: an ultrasound guided erector spinae plane catheter with initial bolus of 30 mL of 0.25% bupivacaine followed by infusion of 0.2% ropivacaine at 10 mL per hour via programmed intermittent bolus.
Study: NCT05569382
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. week: uptitration with one capsules per day, until maximum dosage of three capsules/day.~2-4. week: steady state treatment with the maximum tolerated dose.~5. week: downtitration
Study: NCT06528496
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin is an anthracycline antibiotic
Study: NCT05162755
Drug: S095029
Approvals — FDA: no, EMA: no, PMDA: no
Description: S095029 will be administered via IV infusion every 2 weeks. Once the DLT evaluations period at the second dose level is completed and it is deemed as safe, the dose escalation part 1b will be initiated.
Study: NCT05365581
Drug: ASP2138
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenously or Subcutaneously
Study: NCT05365581
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenously
Study: NCT05365581
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenously
Study: NCT06101095
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC injection as per protocol
Study: NCT06504381
Drug: DB107-FC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally (PO)
Study: NCT06786689
Drug: Azathioprine (AZA)
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: weekly single dose of tab azathioprine 300mg
Study: NCT06237335
Drug: RCT2100
Approvals — FDA: no, EMA: no, PMDA: no
Description: RCT2100 supplied as varying dose strengths administered via oral inhalation using nebulizer
Study: NCT06237335
Drug: RCT2100
Approvals — FDA: no, EMA: no, PMDA: no
Description: RCT2100 supplied as varying dose strengths administered via oral inhalation using nebulizer for 4 weeks
Study: NCT06237335
Drug: RCT2100
Approvals — FDA: no, EMA: no, PMDA: no
Description: RCT2100 supplied at a single dose strength administered via oral inhalation using nebulizer for 12 weeks
Study: NCT06493045
Drug: IRL757
Approvals — FDA: no, EMA: no, PMDA: no
Description: IRL757 capsule
Study: NCT06493045
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule
Study: NCT05081882
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants on this arm will take one placebo capsule orally three times daily for 28 days.
Study: NCT04011839
Drug: Levobupivacaïne
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of Levobupivacaïne instead ropivacaïne
Study: NCT04983173
Drug: Ovarian Stimulation with CC+rFSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: : CC 50 mg/day (Omifin®) + rFSH 150 IU (Ovaleap®) GnRH antagonist: ganirelix 0.25 mg (Orgalutran®) Recombinant human chorionic gonadotropin (rhCG) 250 μg (Ovitrelle®) micronized progesterone 200 mg 3id (Utrogestan®)
Study: NCT04983173
Drug: Ovarian Stimulation with rFSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: rFSH 300 IU rFSH (Ovaleap®) GnRH antagonist: ganirelix 0.25 mg (Orgalutran®) Recombinant human chorionic gonadotropin (rhCG) 250 μg (Ovitrelle®) micronized progesterone 200 mg 3id (Utrogestan®)
Study: NCT06057922
Drug: YL201 for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks (Q3W) as a cycle; and at dose levels of 1.0 mg/kg and 1.2 mg/kg administered on Days 1 and 8 of each Q3W treatment cycle.
Study: NCT04700527
Drug: Short Chain Fatty Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will take the supplement as prescribed to determine if it can help with GI toxicity
Study: NCT04700527
Drug: Tapioca Flour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants taking this will be used as a control group compared to those receiving the SCFA supplement
Study: NCT05671822
Drug: SHR-A1811 and capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: (Arm 1B) Drug: SHR-A1811, administered as an IV infusion Drug：capecitabine, administered orally；
Study: NCT05671822
Drug: SHR-A181, SHR-1701, and capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: (Arm 1C) Drug: SHR-A1811, administered as an IV infusion Drug: SHR-1701, administered as an IV infusion Drug：capecitabine, administered orally；
Study: NCT05671822
Drug: SHR-A1811, SHR-1316, and capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: (Arm 1D) Drug: SHR-A1811, administered as an IV infusion Drug: SHR-1316, administered as an IV infusion Drug：capecitabine, administered orally；
Study: NCT05671822
Drug: SHR-A1811, SHR-1316, capecitabine,and oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: (Arm 1F) Drug: SHR-A1811, administered as an IV infusion Drug: SHR-1316, administered as an IV infusion Drug：capecitabine, administered orally； Drug：oxaliplatin，administered as an IV infusion
Study: NCT05671822
Drug: SHR-A1811, SHR-1316, and 5-FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: (Arm 1G) Drug: SHR-A1811, administered as an IV infusion Drug: SHR-1316, administered as an IV infusion Drug：5-FU，administered as an IV infusion
Study: NCT05671822
Drug: SHR-A1811, SHR-1316, and capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: (Arm 2A) Drug: SHR-A1811, administered as an IV infusion Drug: SHR-1316 administered as an IV infusion; Drug：capecitabine, administered orally；
Study: NCT05671822
Drug: SHR-A1811 and capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: (Arm 2C) Drug: SHR-A1811, administered as an IV infusion Drug：capecitabine, administered orally；
Study: NCT05671822
Drug: SHR-A1811, SHR-1316, and 5-FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: (Arm 2D) Drug: SHR-A1811, administered as an IV infusion Drug: SHR-1316, administered as an IV infusion Drug：5-FU，administered as an IV infusion
Study: NCT04816877
Drug: Opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with acute pancreatitis will be divided into two groups - patient controlled analgesia (PCA) and physician-directed analgesia (PDA). Opioids are routinely administered as standard of care for treating pain associated with acute pancreatitis. Patients in the PCA group will be receiving opioids via a PCA pump, that the patient can use to self-regulate the dose and timing of drug administration. We will follow a specific protocol that has been designed by our pain physician for the PCA pump. Patients in the PDA arm will receive PRN opioids as directed by the physician, which will be administered by the nurse.
Study: NCT05545605
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: the control group (receiving placebo capsule) for 24 weeks.
Study: NCT04356170
Drug: Fluoro Uracil
Normalized name: Fluoro Uracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/m²/j administered continuously at D1 to D5 of each cure, every 3 weeks by intravenous infusion ( so 120 hours)
Study: NCT06510257
Drug: Placebo tablet of Reconyl
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet of placebo Reconyl, 3 times daily
Study: NCT06413537
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06494995
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine metronomic chemotherapy
Study: NCT06012929
Drug: ONC201
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONC201 is an oral medication given once per week
Study: NCT05954143
Drug: BDC-1001
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDC-1001 is an immune-stimulating antibody conjugate (ISAC) designed to be delivered systemically (intravenously) and act locally by targeting HER2-expressing tumors and related metastatic disease for destruction by the innate and adaptive immune systems. BDC-1001 consists of an investigational biosimilar of the humanized monoclonal antibody (mAb) trastuzumab that is chemically conjugated to a toll-like receptor (TLR)7/8 agonist (payload) with an intervening non-cleavable, cell membrane impermeable linker.
Study: NCT06563245
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25mg/m2/dose,
Study: NCT06563245
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m2/dose
Study: NCT06563245
Drug: Bedamustine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180mg/m2/dose; For patients in intermediate/high risk group who did not achieve complete metabolic response at late assessment based on PET/CT results.
Study: NCT05092451
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by IV
Study: NCT05092451
Drug: CAR.70/IL15-transduced CB-NK cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by IV
Study: NCT06402331
Drug: FPI-2265
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSMA ligand radiolabeled with Ac225
Study: NCT05614752
Drug: Fexuprazan
Normalized name: fexuprazan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexuclue Tablet 40mg
Study: NCT04469842
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard immunosuppression of the anti-proliferative class.
Study: NCT05531149
Drug: Trimodulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMP will be administered via IV infusion on 5 consecutive days
Study: NCT05531149
Drug: Placebo (human albumin 1%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMP will be administered via IV infusion on 5 consecutive days
Study: NCT06295796
Drug: MK-8527
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Capsule
Study: NCT06041789
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil placebo tablet
Study: NCT04983862
Drug: Illuminare-1
Normalized name: stila illuminate and shine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Illuminare-1 at 3 dose levels in patients undergoing minimally invasive radical prostatectomy and bilateral pelvic lymph node dissection. Dose levels of the agent will be administered starting at 0.25mg/kg, with increases in dose between cohorts of no more than 0.75 mg/kg until a maximum dose of 3.0mg/kg is reached, if needed. At the dose identified to have the acceptable NMR and no associated DLTs, Illuminare-1 will be studied in up to 20 additional patients at this dose to optimize the imaging protocol and provide additional safety data.
Study: NCT06466486
Drug: FE999302 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: To investigate the effect of FE 999302 on parameters influencing pregnancy rates in women undergoing controlled ovarian stimulation with a fixed dose of follitropin delta in a gonadotropin-releasing hormone (GnRH) antagonist protocol
Study: NCT06245551
Drug: Placebo metered-dose inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo aerosol for inhalation, single dose (given as 2 actuations)
Study: NCT05286970
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abdominal subcutaneous injection
Study: NCT03590821
Drug: Celecoxib 200mg capsule
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: daily administration of celecoxib
Study: NCT05900531
Drug: K-757
Normalized name: K
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered orally
Study: NCT05900531
Drug: Matching placebo to K-757 and matching placebo to K-833
Approvals — FDA: no, EMA: no, PMDA: no
Description: both administered orally
Study: NCT05900531
Drug: K-757 and K-833
Normalized name: K
Approvals — FDA: no, EMA: no, PMDA: no
Description: both administered orally
Study: NCT06702345
Drug: Clindamycin
Normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral clindamycin pretreatment, 3 times a day 600mg, given the five days before toxigenic C. difficile exposure
Study: NCT06701760
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: infusion of sodium chloride
Study: NCT05676463
Drug: Antiandrogen Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive SOC ADT
Study: NCT06703970
Drug: Corticosteroid Injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 milliliters (mL) injection of corticosteroid (1cc Kenalog, 4cc Xylocaine) Kenalog - 40 (triamcinolone acetonide injectable suspension, USP) Xylocaine - MPF (lidocaine HCl Injection, USP)
Study: NCT06195267
Drug: Blank control
Normalized name: acid black 52
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients only received standard treatment and care.
Study: NCT05824975
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin will be administered intravenously at a dose of 75 mg/m2 on Day 3 every 3-week (21-day) cycle for up to 6 cycles.
Study: NCT03904498
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets
Study: NCT06553547
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo solution
Study: NCT05063539
Drug: LY3372689
Approvals — FDA: no, EMA: no, PMDA: no
Description: given orally
Study: NCT06205095
Drug: Lyophilized concentrate of human coagulation von Willebrand Factor and factor VIII
Normalized name: factor VIII, human / von Willebrand factor, human Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wilate® is a plasma-derived, highly purified concentrate administered through intravenous injection. Wilate® contains an average VWF ristocetin cofactor activity to FVIII activity at ratio of 1:1.
Study: NCT06329141
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily oral administration
Study: NCT05360680
Drug: CUE-102
Approvals — FDA: no, EMA: no, PMDA: no
Description: CUE-102 is a novel fusion protein developed for the treatment of patients with WT1-positive malignancies.
Study: NCT04961567
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT05483998
Drug: TLC-2716
Normalized name: chlorpheniramine maleate / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Ed-TLC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: TLC-2716
Study: NCT05995535
Drug: LFX/PGB
Approvals — FDA: no, EMA: no, PMDA: no
Description: lofexidine tablets 0.18mg tabs~pregabalin capsules 100mg and 25mg
Study: NCT05995535
Drug: LFX/PLA-PGB
Approvals — FDA: no, EMA: no, PMDA: no
Description: lofexidine tablets 0.18mg tabs~pregabalin capsules 0mg
Study: NCT06797960
Drug: Intra articular injection of HA
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra articular injection of HA
Study: NCT05353829
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: When accepted inclusion the patient will be included in SRQ, and thereafter randomised for Methotrexate per oral or subcutaneous administration
Study: NCT04704999
Drug: Artemether 20 mg-Lumefantrine 120 mg
Normalized name: artemether
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Artemether-lumefantrine will be given twice daily over 3 days. Whole tablets will be given based on weight bands.
Study: NCT06346262
Drug: Valtoco Nasal Product
Normalized name: Valtoco Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication dosing will follow recommendations in the Valtoco package insert and managed by the epilepsy clinician.
Study: NCT06007651
Drug: LY3885125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06007651
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT05402332
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo equivalent
Study: NCT05800665
Drug: RO7656594
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7656594 will be administered orally at specified dose on specified days.
Study: NCT05547750
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Similar-looking placebo tablets
Study: NCT05868525
Drug: Aspirin 325Mg Tab, Aspirin 81Mg Tab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be administrated daily oral Aspirin 81 mg or oral Aspirin 325 mg according to their assigned group after randomization.
Study: NCT04956432
Drug: SHR4640
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR4640 Dose 1 ,tablets, QD
Study: NCT06550141
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Alkylating agent
Study: NCT06364228
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intranasal spray liquid administration. Oxytocin delivered 2 puffs to each nostril daily for 21 days. The first single dose will be administered at the clinic (visit 1).